Helix BioPharma Corp. (HBPCF)
OTCMKTS · Delayed Price · Currency is USD
1.734
+1.134 (189.00%)
At close: Oct 22, 2025
Helix BioPharma Balance Sheet
Financials in millions CAD. Fiscal year is August - July.
Millions CAD. Fiscal year is Aug - Jul.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Oct '25 Oct 31, 2025 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 | 2016 - 2020 |
Cash & Equivalents | 0.5 | 0.07 | 1.08 | 0.81 | 3.25 | 3.57 | Upgrade |
Cash & Short-Term Investments | 0.5 | 0.07 | 1.08 | 0.81 | 3.25 | 3.57 | Upgrade |
Cash Growth | 118.42% | -93.99% | 33.79% | -75.15% | -8.78% | -15.82% | Upgrade |
Other Receivables | 0.04 | 0.12 | 0.05 | 0.06 | 0.28 | 0.35 | Upgrade |
Receivables | 0.04 | 0.12 | 0.05 | 0.06 | 0.28 | 0.35 | Upgrade |
Prepaid Expenses | 0.14 | 0.22 | 0.32 | 0.13 | 0.16 | 0.1 | Upgrade |
Total Current Assets | 0.68 | 0.41 | 1.46 | 1 | 3.7 | 4.02 | Upgrade |
Property, Plant & Equipment | 0 | 0 | 0.03 | 0.03 | 0.04 | 0.05 | Upgrade |
Other Intangible Assets | 18.39 | 18.39 | 0 | - | - | - | Upgrade |
Total Assets | 19.07 | 18.8 | 1.49 | 1.03 | 3.73 | 4.07 | Upgrade |
Accounts Payable | 2.06 | 2.3 | 0.86 | 0.49 | 0.6 | 1.47 | Upgrade |
Accrued Expenses | 0.59 | 0.58 | 0.72 | 0.38 | 0.35 | 0.38 | Upgrade |
Short-Term Debt | 0.35 | 0.34 | - | - | - | - | Upgrade |
Current Portion of Long-Term Debt | - | - | - | - | 2.47 | 2.03 | Upgrade |
Current Portion of Leases | 0 | 0 | - | - | - | - | Upgrade |
Other Current Liabilities | - | - | - | 1 | -0 | - | Upgrade |
Total Current Liabilities | 3 | 3.22 | 1.58 | 1.87 | 3.41 | 3.87 | Upgrade |
Long-Term Debt | - | - | - | - | - | 1.58 | Upgrade |
Other Long-Term Liabilities | - | - | - | - | 0 | - | Upgrade |
Total Liabilities | 3 | 3.22 | 1.58 | 1.87 | 3.41 | 5.46 | Upgrade |
Common Stock | 180.78 | 179.29 | 158.57 | 152.07 | 147.51 | 139.66 | Upgrade |
Additional Paid-In Capital | 48.3 | 48.3 | 47.36 | 44.14 | 37.59 | 27.87 | Upgrade |
Retained Earnings | -216.88 | -215.88 | -210.67 | -201.41 | -195.12 | -188.55 | Upgrade |
Comprehensive Income & Other | 3.87 | 3.87 | 4.65 | 4.36 | 10.34 | 19.63 | Upgrade |
Total Common Equity | 16.07 | 15.59 | -0.09 | -0.85 | 0.32 | -1.39 | Upgrade |
Shareholders' Equity | 16.07 | 15.59 | -0.09 | -0.85 | 0.32 | -1.39 | Upgrade |
Total Liabilities & Equity | 19.07 | 18.8 | 1.49 | 1.03 | 3.73 | 4.07 | Upgrade |
Total Debt | 0.35 | 0.34 | - | - | 2.47 | 3.61 | Upgrade |
Net Cash (Debt) | 0.15 | -0.27 | 1.08 | 0.81 | 0.78 | -0.05 | Upgrade |
Net Cash Growth | -36.40% | - | 33.79% | 3.06% | - | - | Upgrade |
Net Cash Per Share | 0.00 | -0.00 | 0.02 | 0.02 | 0.03 | -0.00 | Upgrade |
Filing Date Shares Outstanding | 76.38 | 76.38 | 49.02 | 43.33 | 34.86 | 28.49 | Upgrade |
Total Common Shares Outstanding | 76.38 | 74.16 | 49.02 | 40 | 34.36 | 28.23 | Upgrade |
Working Capital | -2.33 | -2.81 | -0.12 | -0.88 | 0.28 | 0.14 | Upgrade |
Book Value Per Share | 0.21 | 0.21 | -0.00 | -0.02 | 0.01 | -0.05 | Upgrade |
Tangible Book Value | -2.32 | -2.8 | -0.09 | -0.85 | 0.32 | -1.39 | Upgrade |
Tangible Book Value Per Share | -0.03 | -0.04 | -0.00 | -0.02 | 0.01 | -0.05 | Upgrade |
Machinery | 1.22 | 1.22 | 1.46 | 1.44 | 1.44 | 1.43 | Upgrade |
Leasehold Improvements | - | - | 0.36 | 0.36 | 0.36 | 0.36 | Upgrade |
Updated Oct 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.